EsoCap announces publication of comprehensive Phase II results demonstrating ESO-101’s effectiveness in eosinophilic esophagitis Detailed results of the ACESO Phase II study published in the peer-reviewed medical journal Alimentary Pharmacology & TherapeuticsESO-101 leverages EsoCap’s unique drug delivery technology to...

EsoCap completes patient recruitment in ACESO Phase II trial in eosinophilic esophagitis EsoCap's novel targeted delivery platform is designed to increase mucosal contact time and drug deposition in the esophagus ESO-101, EsoCap's lead product candidate, consists of a capsule with a...

EsoCap announces first patient enrolled in Phase II eosinophilic esophagitis trial Randomized, placebo-controlled, double-blind Phase II trial to treat 42 patients ongoing in four European countries with ESO-101ESO-101, EsoCap’s lead product candidate, consists of a capsule with a...

EsoCap – unique targeted application platform to treat the upper gastrointestinal tract EsoCap’s targeted application technology drastically increases mucosal contact time and enables effective local treatment of various esophageal diseases for the first timeProof of principle in human...